litlas
ログインアカウント作成

Daniel Castellano

1999–2025 年に発表

144
論文数
38,639
被引用数
74
h 指数
139
i10 指数

被引用数

Daniel Castellano の年別被引用数1956 年: 被引用 1 件2000 年: 被引用 10 件2001 年: 被引用 6 件2002 年: 被引用 8 件2003 年: 被引用 2 件2004 年: 被引用 3 件2005 年: 被引用 6 件2006 年: 被引用 4 件2007 年: 被引用 9 件2008 年: 被引用 10 件2009 年: 被引用 10 件2010 年: 被引用 12 件2011 年: 被引用 30 件2012 年: 被引用 61 件2013 年: 被引用 64 件2014 年: 被引用 60 件2015 年: 被引用 73 件2016 年: 被引用 278 件2017 年: 被引用 418 件2018 年: 被引用 567 件2019 年: 被引用 1,626 件2020 年: 被引用 2,120 件2021 年: 被引用 2,194 件2022 年: 被引用 1,560 件2023 年: 被引用 1,240 件2024 年: 被引用 2,021 件2025 年: 被引用 1,068 件2026 年: 被引用 31 件1957〜1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,243 件、この内訳の 22.3%中国: 引用元論文 2,010 件、この内訳の 10.5%イタリア: 引用元論文 1,285 件、この内訳の 6.7%イギリス: 引用元論文 1,170 件、この内訳の 6.1%フランス: 引用元論文 1,051 件、この内訳の 5.5%ドイツ: 引用元論文 893 件、この内訳の 4.7%スペイン: 引用元論文 832 件、この内訳の 4.4%日本: 引用元論文 768 件、この内訳の 4%カナダ: 引用元論文 737 件、この内訳の 3.9%オーストラリア: 引用元論文 493 件、この内訳の 2.6%オランダ: 引用元論文 483 件、この内訳の 2.5%スイス: 引用元論文 470 件、この内訳の 2.5%
0%22.3%その他 24.3%

機関

分野

  • Medicine81.3%
  • Biochemistry, Genetics and Molecular Biology11.9%
  • Immunology and Microbiology4.3%
  • Engineering0.6%
  • Computer Science0.3%
  • Neuroscience0.2%
  • その他1.4%

トピック

  • Cancer Immunotherapy and Biomarkers14.2%
  • Bladder and Urothelial Cancer Treatments5.9%
  • Renal cell carcinoma treatment5.7%
  • Immunotherapy and Immune Responses3.5%
  • Ferroptosis and cancer prognosis3.3%
  • Cancer Genomics and Diagnostics3%
  • その他64.4%

共著者

全論文

検索で開く
  1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    著者: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 被引用: 4,643

  2. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    著者: Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma - New England Journal of Medicine 2015 被引用: 5,890

  3. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    著者: Thomas Powles, Jonathan E. Rosenberg, Guru Sonpavde, Yohann Loriot, Ignacio Durán, Jae‐Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Chunzhang Wu, Mary S. Campbell, Maria Matsangou, Daniel P. Petrylak - New England Journal of Medicine 2021 被引用: 1,155

  4. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

    著者: Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, Daniel Castellano, Giuseppe Fornarini, Jian‐Ri Li, Mahmut Gümüş, Nataliya Mar, Yohann Loriot, Aude Fléchon, Ignacio Durán, Alexandra Drakaki, Sujata Narayanan, Xuesong Yu, Seema Rao Gorla, Blanca Homet Moreno, Michiel S. van der Heijden - New England Journal of Medicine 2024 被引用: 914

  5. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    著者: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 被引用: 3,714

  6. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

    著者: Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah, Romain Banchereau, Bernadett Szabados, Kobe Yuen, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Maurizio Perdicchio, Jingbin Zhang, David S. Shames, Viraj Degaonkar, Xiaodong Shen, Corey Carter, Carlos Bais, Joaquim Bellmunt, Sanjeev Mariathasan - Nature 2021 被引用: 629

  7. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    著者: Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R. Plimack, Noah M. Hahn, Ronald de Wit, Lei Pang, Mary J. Savage, Rodolfo F. Perini, Stephen J. O’Keefe, Dean F. Bajorin, Joaquim Bellmunt - The Lancet Oncology 2017 被引用: 1,342

  8. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

    著者: Thomas Powles, Ignacio Durán, Michiel S. van der Heijden, Yohann Loriot, Nicholas J. Vogelzang, Ugo De Giorgi, Stéphane Oudard, Margitta Retz, Daniel Castellano, Aristotelis Bamias, Aude Fléchon, Gwénaëlle Gravis, Syed A. Hussain, Toshimi Takano, Ning Leng, Edward E. Kadel, Romain Banchereau, Priti S. Hegde, Sanjeev Mariathasan, Na Cui, Xiaodong Shen, Christina Louise Derleth, Marjorie C. Green, Alain Ravaud - The Lancet 2017 被引用: 1,416

  9. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

    著者: Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida, Ignacio Durán, Simon J. Crabb, Michiel S. van der Heijden, Bernadett Szabados, Albert Font Pous, Gwénaëlle Gravis, Urbano Anido, Andrew Protheroe, Alain Ravaud, Denis Maillet, María José Méndez, Cristina Suárez, Mark Linch, Aaron Prendergast, Pieter‐Jan van Dam, Diana Stanoeva, Sofie Daelemans, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano - Nature Medicine 2019 被引用: 571

  10. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

    著者: Ronald de Wit, Johann S. de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean‐Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Théodore, Susan Feyerabend, Carole Hélissey, Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Daniel Castellano - New England Journal of Medicine 2019 被引用: 660

  11. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    著者: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli ほか 127 名 - The Lancet Oncology 2020 被引用: 498

  12. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    著者: Robert J. Motzer, David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, M. Brent McHenry, Chung‐Wei Lee, Jennifer L. McCarthy, Flavia Ejzykowicz, Nizar M. Tannir - Cancer 2022 被引用: 263

  13. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

    著者: Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Toni K. Choueiri, Shruti Shally Saggi, M. Brent McHenry, Robert J. Motzer - ESMO Open 2020 被引用: 522

  14. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    著者: Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H. O’Donnell, Jonathan E. Rosenberg, Daniel M. Geynisman, Daniel P. Petrylak, Jean Hoffman‐Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S. van der Heijden, Cora N. Sternberg, Nicole N. Davarpanah, Thomas Powles - The Lancet Oncology 2021 被引用: 412

  15. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

    著者: Bernadett Szabados, Mark Kockx, Zoe J. Assaf, Pieter‐Jan van Dam, Alejo Rodríguez‐Vida, Ignacio Durán, Simon J. Crabb, Michiel S. van der Heijden, Albert Font Pous, Gwénaëlle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, María José Méndez, Cristina Suárez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles - European Urology 2022 被引用: 190

  16. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    著者: Jonathan E. Rosenberg, Thomas Powles, Guru Sonpavde, Yohann Loriot, Ignacio Durán, J.-L. Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Ronac Mamtani, Chunzhang Wu, Maria Matsangou, Mary S. Campbell, Daniel P. Petrylak - Annals of Oncology 2023 被引用: 153

  17. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    著者: Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann S. de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Simon Chowdhury, Caroline S. Clarke, Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki ほか 18 名 - European Journal of Cancer 2023 被引用: 157

  18. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

    著者: Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Eduardo Richardet, Katriina Peltola, Ajjai Alva, Michael A. Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas Gauler, Christian Kollmannsberger, Fabio A.B. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Cancer 2020 被引用: 337

  19. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

    著者: David F. McDermott, Jae‐Lyun Lee, Marek Ziobro, Cristina Suárez, Przemysław Langiewicz, В. Б. Матвеев, Paweł Wiechno, Rustem Gafanov, Piotr Tomczak, Frédéric Pouliot, Frede Donskov, B. Yа. Alekseev, Sang Joon Shin, Georg A. Bjarnason, Daniel Castellano, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins - Journal of Clinical Oncology 2021 被引用: 287

  20. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

    著者: Michael J. Morris, Daniel Castellano, Ken Herrmann, Johann S. de Bono, Neal D. Shore, Kim N., Michael J. Crosby, Josep M. Piulats, Aude Fléchon, Xiao X. Wei, Hakim Mahammedi, Guilhem Roubaud, Hana Študentová, James Nagarajah, Begoña Mellado, Álvaro Montesa-Pino, Euloge Kpamegan, Samson Ghebremariam, Teri Kreisl, Celine Wilke, Katja Lehnhoff, Oliver Sartor, Karim Fizazi - The Lancet 2024 被引用: 258

  21. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

    著者: Thomas Powles, Zoe J. Assaf, Viraj Degaonkar, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Himanshu Sethi, Alexey Aleshin, Yi Shi, Nicole N. Davarpanah, Corey Carter, Joaquim Bellmunt, Sanjeev Mariathasan - European Urology 2023 被引用: 131

  22. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

    著者: Nizar M. Tannir, Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Sangeeth M. George, Frede Donskov, Michael B. Atkins, Howard Gurney, C.K. Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, Ruowei Jiang, Heshani Desilva, В. Э. Федоров, Chung‐Wei Lee, Robert J. Motzer - Annals of Oncology 2024 被引用: 192

  23. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

    著者: Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Noah M. Hahn, Mary J. Savage, Xiao Fang, James Luke Godwin, Tara L. Frenkl, Blanca Homet Moreno, Ronald de Wit, Elizabeth R. Plimack - Journal of Clinical Oncology 2020 被引用: 292

  24. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    著者: Brian I. Rini, Bernard Escudier, Piotr Tomczak, А. Д. Каприн, Cezary Szczylik, Thomas E. Hutson, M. Dror Michaelson, В. А. Горбунова, Martin Gore, И. Г. Русаков, Sylvie Négrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J. Motzer - The Lancet 2011 被引用: 1,849